Are Non-invasive Multi-cancer Early Cancer Detection Tests the Future?

Digestive Diseases and Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Language: Английский

---

Ethical Considerations and Implications of Multi-Cancer Early Detection Screening: Reliability, Access and Cost to Test and Treat

Cambridge Quarterly of Healthcare Ethics, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 10

Published: Jan. 3, 2025

Abstract This essay focuses on the ethical considerations and implications of providing a universal multi-cancer screening test as best approach to reduce societal cancer burden in society with limited funds, resources, infrastructure. With 1.9 million diagnoses each year United States, 86% all cancers diagnosed individuals over age 50, tools approved for only four types (breast, cervical, colorectal, lung cancer), it seems that detect most early is easy administer, accurate cost-effective, would be worth considering. Whole-body magnetic resonance imaging multi-marker blood are two main technologies we will discuss test. However, understand appreciate clinical breakthrough such test, must first consider accessibility efficacy current methods. We conclude closer examination implementing Galleri detection tool adamantly advocated by company developed this blood-based

Language: Английский

---

Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies

International Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 12, 2025

Abstract Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number cancers, such as gastric, colorectal, lung, breast, cervical cancer. Additionally, several cancers inadequately screened, hindering early 45.5% cases. In contrast, Multi-Cancer Detection (MCED) assays offer simultaneous multiple from liquid biopsy identify molecular changes before symptom onset. These tests assess DNA mutations, abnormal methylation patterns, fragmented DNA, other tumor-derived biomarkers, indicating presence predicting its origin. Moreover, MCED concurrently detect without recommended protocols, potentially revolutionizing management. Large trials have reported promising results, achieving 50–95% sensitivity 89–99% specificity for types. However, challenges, regarding improving accuracy, addressing ethical issues (e.g., psychosocial impact assessment), integrating into healthcare systems, must be addressed to achieve widespread adoption. Furthermore, prospective multi-institutional studies crucial demonstrating clinical benefits in diverse populations. This review provides an overview principles, development status, significance tests, discusses their potential challenges.

Language: Английский

---

The psychological impact of screening with a multicancer early detection test

The Lancet Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Pan-cancer secreted proteome and skeletal muscle regulation: insight from a proteogenomic data-driven knowledge base

Functional & Integrative Genomics, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 15, 2025

Language: Английский

---

The long road to unbiased estimates of pancreatic cancer incidence in the hereditary breast and ovarian cancer syndrome

Cancer, Journal Year: 2025, Volume and Issue: 131(3)

Published: Jan. 22, 2025

The determination of unbiased cancer risk estimates in hereditary breast and ovarian syndrome (HBOC) poses several challenges. article by Katona colleagues is the first analysis to provide pancreatic incidence HBOC generated from a prospectively followed cohort B RCA mutation carriers, which addresses potential biases inherent retrospective pedigree analyses.

Language: Английский

---

Potential and Limitations of the MinION Nanopore array for miRNA-Enabled Early Cancer Detection.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 21, 2025

Summary The 2024 Nobel Prize in Physiology or Medicine was awarded to the pioneers who reported that microRNAs (miRNAs) regulate and direct switch between physiological pathological pathways via their over- under-expression. discovery has not yielded any health benefit primarily due raw data with no clear distinction healthy diseased blood samples. MiRNAs exist at femtomolar level biological fluids, typically quantified using amplification-based techniques. Experimental nanopores have illustrated potential for trace analysis including amplification-free miRNA quantification. We repurposed MinION, only commercially available nanopore-array device, developed unique probes protocols quantify urine. Our report revealed (i) copies are proportional total RNA isolated from biospecimen, (ii) several known cancer biomarkers were 1.8-fold overexpressed samples breast, prostate pancreatic patients compared healthy. In contrast literature reports sample variability undetectable after normalization same content. Here earlier confirmed, conclusions extended ovarian, lung, colorectal cancer. of ready-to-use MinION/Yenos platform multiple early detection (MCED) urine is discussed.

Language: Английский

---

Multicancer Detection (MCD) Testing in Gastrointestinal Cancers: An Evolving Tool for Early Diagnosis

Current Gastroenterology Reports, Journal Year: 2025, Volume and Issue: 27(1)

Published: March 6, 2025

The current review aims to summarize the benefits and limitations of novel multicancer detection tests (MCD) for diagnosing gastrointestinal (GI) malignancies. Traditional cancer screening methods can reduce deaths in malignancies involving GI tract. For cancers, options vary by type often involve invasive techniques with limited sensitivity. MCDs offer a promising, non-invasive (simple blood draw) alternative analyzing biomarkers such as cell-free DNA RNA using advanced machine learning detect cancers across multiple organ sites. Large studies like PATHFINDER trial THUNDER study have demonstrated feasibility accuracy MCD assays identifying signals, high sensitivity specificity some organs that lack routine (e.g., liver, pancreas, stomach). Despite these advancements, testing faces challenges, including costs, FDA approval, false positives, data on clinical utility reducing cancer-specific mortality. should not be substitute age-appropriate screenings but may complement existing methods, particularly no tools, cholangiocarcinoma pancreatic cancer. Clinicians need discuss MCDs, potential overdiagnosis, patient anxiety, financial burden due insurance coverage gaps. is test augment traditional screening. As role evolves, further research essential establish how it will integrated into practice, ensuring informed, shared decision-making patients.

Language: Английский

---

Multicancer early detection testing: Guidance for primary care discussions with patients

Cancer, Journal Year: 2025, Volume and Issue: 131(7)

Published: April 1, 2025

Multicancer early detection (MCED) tests are an emerging technology for cancer screening. MCED can detect signals from multiple cancers concurrently in biological samples such as blood, urine, saliva, or other bodily fluids. Some suggest the most likely origin, whereas others report detected somewhere body. Although some currently commercially available, none approved by Food and Drug Administration endorsed any clinical practice guideline recommendation. Most insurance companies do not cover testing. have yet been evaluated safety effectiveness randomized controlled trials. Because patients already asking test prescriptions interpretation of results acquired elsewhere, clinicians should be prepared to discuss what is known about benefits, risks, uncertainties testing, including performance characteristics screening populations preferred follow-up strategies positive results. At this time, feel obligated initiate discussions testing with their patients. However, engage who inquire getting tested previous shared decision-making, take opportunity offer help complete age- sex-appropriate guideline-recommended screenings. In article, current evidence issues around summarized, a framework decision-making provided.

Language: Английский

---

An Innovative Real-Time Cell Viability Analysis: A Cutting-Edge Flexible Bioimpedance Sensor

Chemosensors, Journal Year: 2025, Volume and Issue: 13(4), P. 132 - 132

Published: April 6, 2025

There are many compounds used to treat cancer, but still, only 20% of proposed anticancer agents have been commercialized after clinical trials due serious side effects and unsatisfactory results. To screen potential drugs precisely quickly, this study develops a flexible bioimpedance sensor. The sensor positively detects the half maximal inhibitory concentration (IC50) in real time by analyzing phase angle changes during cell mortality. best results achieved using probe separation A12B34 at logarithmic frequencies 163 Hz 77.87 kHz. At these two frequencies, there is linear relationship with 0% 50% dead cells. Dividing shows 17.98% change angle, which allows self-correction insensitivity number A custom measurement device developed for detection kHz, respectively. This novel that precise fast high-throughput analysis detect inhibition cancer time. an alternative traditional chemical methods because it faster, cheaper, more accurate.

Language: Английский

---